AVITA Medical to Host Investor Webinar Briefing
AVITA Medical (NASDAQ: RCEL, ASX: AVH), a leader in regenerative medicine for wound care and skin restoration, has announced an upcoming investor webinar briefing on August 13, 2024, at 4:00 p.m. PDT (August 14, 2024, at 9:00 a.m. AEST). The presentation will be led by CEO Jim Corbett and CFO David O'Toole, covering financial and business results from the company's recent second-quarter 2024 earnings.
Shareholders and potential investors are invited to attend the webinar, which will include a Q&A session. Participants can submit questions through the registration page. The event will be hosted via Zoom, with a replay available on the AVITA Medical website following the presentation.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), leader nella medicina rigenerativa per la cura delle ferite e il ripristino della pelle, ha annunciato un prossimo webinar per gli investitori che si terrà il 13 agosto 2024, alle 16:00 PDT (14 agosto 2024, alle 9:00 AEST). La presentazione sarà guidata dal CEO Jim Corbett e dal CFO David O'Toole, coprendo i risultati finanziari e aziendali dell'ultima risultato economico del secondo trimestre 2024.
Gli azionisti e i potenziali investitori sono invitati a partecipare al webinar, che includerà una sessione di domande e risposte. I partecipanti possono inviare domande attraverso la pagina di registrazione. L'evento sarà ospitato tramite Zoom, con una registrazione disponibile sul sito web di AVITA Medical successivamente alla presentazione.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), un líder en medicina regenerativa para el cuidado de heridas y la restauración de la piel, ha anunciado un próximo webinario para inversionistas que se llevará a cabo el 13 de agosto de 2024, a las 4:00 p.m. PDT (14 de agosto de 2024, a las 9:00 a.m. AEST). La presentación estará a cargo del CEO Jim Corbett y el CFO David O'Toole, cubriendo los resultados financieros y empresariales de las recientes ganancias del segundo trimestre de 2024.
Los accionistas y potenciales inversionistas están invitados a asistir al webinario, que incluirá una sesión de preguntas y respuestas. Los participantes pueden enviar preguntas a través de la página de registro. El evento se llevará a cabo a través de Zoom, con una repetición disponible en el sitio web de AVITA Medical después de la presentación.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), 상처 치료 및 피부 복원을 위한 재생 의학 분야의 선두주자가, 2024년 8월 13일 오후 4시 PDT (2024년 8월 14일 오전 9시 AEST)에 개최될 투자자 웨비나 브리핑을 발표했습니다. 발표는 CEO Jim Corbett와 CFO David O'Toole가 진행하며, 회사의 최근 2024년 2분기 수익에 대한 재무 및 사업 결과를 다룰 예정입니다.
주주 및 잠재 투자자들은 질문과 답변 세션이 포함된 웨비나에 참석하도록 초대받습니다. 참가자는 등록 페이지를 통해 질문을 제출할 수 있습니다. 이벤트는 Zoom을 통해 진행되며, 발표 후 AVITA Medical 웹사이트에서 재생성이 가능합니다.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), un leader dans la médecine régénérative pour le soin des plaies et la restauration de la peau, a annoncé un prochain webinaire pour investisseurs qui aura lieu le 13 août 2024 à 16h00 PDT (14 août 2024 à 9h00 AEST). La présentation sera animée par CEO Jim Corbett et CFO David O'Toole, couvrant les résultats financiers et commerciaux des résultats du deuxième trimestre 2024.
Les actionnaires et les investisseurs potentiels sont invités à assister au webinaire, qui inclura une session de questions-réponses. Les participants peuvent soumettre des questions via la page d'inscription. L'événement sera organisé via Zoom, avec une rediffusion disponible sur le site web d’AVITA Medical après la présentation.
AVITA Medical (NASDAQ: RCEL, ASX: AVH), ein führendes Unternehmen in der regenerativen Medizin für Wundversorgung und Hautrestaurierung, hat ein bevorstehendes Investor-Webinar für den 13. August 2024 um 16:00 Uhr PDT (14. August 2024 um 9:00 Uhr AEST) angekündigt. Die Präsentation wird von CEO Jim Corbett und CFO David O'Toole geleitet und umfasst die finanziellen und geschäftlichen Ergebnisse der aktuellen Ergebnisse des zweiten Quartals 2024.
Aktionäre und potenzielle Investoren sind eingeladen, an dem Webinar teilzunehmen, das eine Fragen-und-Antworten-Runde beinhalten wird. Die Teilnehmer können Fragen über die Registrierungsseite einreichen. Die Veranstaltung wird über Zoom gehostet, und eine Aufzeichnung wird nach der Präsentation auf der AVITA Medical-Website bereitgestellt.
- None.
- None.
VALENCIA, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on August 13, 2024, at 4:00 p.m. Pacific Daylight Time (August 14, 2024, at 9:00 a.m. Australian Eastern Standard Time).
The webinar presentation will cover financial and business results from our recent second-quarter 2024 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.
To register for the presentation, please follow this Zoom link:
https://us02web.zoom.us/webinar/register/WN_SGTRZkxTSG2UD5-GTu1F2g
A replay will be available on the AVITA Medical website, ir.avitamedical.com, following the presentation.
About AVITA Medical, Inc.
AVITA Medical® is a commercial-stage regenerative medicine company transforming the standard of care in wound care management and skin restoration with innovative devices. At the forefront of our platform is the RECELL® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. RECELL harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ Cells, delivering a transformative solution at the point-of-care. This breakthrough technology serves as the catalyst for a new treatment paradigm enabling improved clinical outcomes. AVITA Medical also holds the exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, in the United States.
In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns, full-thickness skin defects, and vitiligo. The RECELL System is TGA-registered in Australia, has received CE-mark approval in Europe, and has PMDA approval in Japan.
To learn more, visit www.avitamedical.com.
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
FAQ
When is AVITA Medical (RCEL) hosting its investor webinar briefing?
Who will be presenting at AVITA Medical's (RCEL) investor webinar?
What topics will be covered in AVITA Medical's (RCEL) investor webinar?
How can investors register for AVITA Medical's (RCEL) webinar presentation?
Will there be a replay available of AVITA Medical's (RCEL) investor webinar?
